Morgan Stanley raised price targets and ratings for Ultragenyx Pharmaceutical.
9 reports, 1 independent
Updated Sep 23
Gone quiet
- Reports
- 9
- Developments
- 1
- Repetition
- 89%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley raised price targets and ratings for Ultragenyx Pharmaceutical.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ultragenyx Pharmaceutical
biopharmaceutical company based in Novato, California, United States
Nothing else this week.
-
Morgan Stanley
U.S. investment bank
Related events
- Morgan Stanley dropped its target price on Lowe's shares, with Benzinga and MarketBeat reporting the change.
- Financial institutions Morgan Stanley, Royal Bank of Canada, and Citigroup issued various rating and price target updates for Howmet Aerospace.
- Morgan Stanley reduced its price target on DT Midstream, while Scotiabank set a new price objective, as reported by Benzinga.
- Morgan Stanley provided analyst ratings and price targets for Steel Dynamics, whose stock trades on NASDAQ.
- Morgan Stanley and Barclays raised price forecasts for technology stocks, citing positive revenue growth and AI chip demand.